Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction
NCT: NCT07415330 · NOT_YET_RECRUITING
Brief Summary
This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.
Frequently Asked Questions
What is Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction?
Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction is a clinical trial registered under NCT07415330. Current status: NOT_YET_RECRUITING.
What is the status of NCT07415330?
The current status of NCT07415330 (Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction) is: NOT_YET_RECRUITING.
When did Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction start?
Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction started on 2026-07-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.